The Company supports transformational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. Gynov provides solutions that bring a high benefit-risk ratio to patients and will likely be recommended by healthcare professionals, owing to a well-documented scientific track record. Gynov, short for Gynecological Innovation, was founded by Pierre-Yves Mousset in France in 2016.